Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Latest CARTITUDE-4 Data Highlight the Benefits of Cilta-Cel in Multiple Myeloma
CARTITUDE-4 trial data at IMS 2024 shows cilta-cel significantly improves overall survival (HR .55) and progression-free survival (HR .29) in lenalidomide-refractory multiple myeloma patients, with no new safety concerns.
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus ...
CARVYKTI® reduces death risk by 45% in lenalidomide-refractory multiple myeloma patients, significantly extending overall survival in the CARTITUDE-4 study, presented at the 2024 International Myeloma Society Annual Meeting.
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA approves Formycon AG's biosimilar FYB202/OtulfiTM (ustekinumab-aauz) for treating Crohn’s disease, ulcerative colitis, moderate-to-severe plaque psoriasis, and active psoriatic arthritis.
Amivantamab Accolades Add Up for NSCLC
Amivantamab (Rybrevant) has received 3 FDA approvals for EGFR-mutated non–small cell lung cancer (NSCLC), including first-line use in EGFR exon 20 insertion mutations, a chemotherapy-free regimen with lazertinib for exon 19 deletions or exon 21 L858R mutations, and with standard chemotherapy for patients with exon 19 deletions or exon 21 L858R mutations post-EGFR TKI treatment. The MARIPOSA trial evaluated amivantamab plus lazertinib versus osimertinib, showing superior progression-free survival.
Cepheus Phase 3 Study Shows Improvement for Patients With Multiple Myeloma
Johnson & Johnson's darzalex faspro treatment showed 60.9% improvement in eliminating cancer cells and 43% reduction in progression or death for newly diagnosed multiple myeloma patients in Cepheus phase 3 trial.
Talquetamab Combo Updates Show Durable Responses in Heavily Pretreated Patients
Talquetamab, a bispecific GPRC5D-directed CD3 T-cell engager, demonstrated durable responses in multiple myeloma patients with 4-5 prior therapies in TRIMM-2 and RedirecTT trials. Updated phase 1b results showed an 81.8% ORR and 15.5-month median PFS in the TRIMM-2 triplet arm, and a 79.5% ORR at 18 months in the RedirecTT-1 dual bispecific arm. Both combinations showed robust durability and efficacy, even in high-risk patients with extramedullary disease.
Related Clinical Trials:
Daratumumab With VRd Betters MRD Negativity in Transplant-Ineligible Myeloma
The CEPHEUS trial showed that adding daratumumab to the VRd regimen improved MRD negativity rates to 60.9% vs 39.4% with VRd alone in newly diagnosed multiple myeloma patients ineligible for or deferred transplant, with a CR or better rate of 81.2% vs 61.6%. The subcutaneous daratumumab-based regimen demonstrated deep, durable responses and reduced disease progression risk, potentially becoming a new standard for this patient population.
Related Clinical Trials:
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep ...
DARZALEX FASPRO® in maintenance therapy significantly increased MRD-negativity rate at 12 months compared to lenalidomide alone, improving 30-month progression-free survival in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.
Related Clinical Trials:
Teclistimab Demonstrates Continued Deep, Durable Responses in Long-Term Follow-Up
Long-term follow-up of MajesTEC-1 trial shows teclistamab maintains deep and durable responses in relapsed/refractory multiple myeloma, with 63% overall response rate and 46.1% achieving CR or better. Median DOR, PFS, and OS increased to 24, 11.4, and 22.2 months, respectively. Safety profile consistent, with notable decrease in severe infections over time.
Related Clinical Trials:
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi
FYB202/Otulfi® received EC approval for subcutaneous and intravenous formulations, approved for Crohn’s disease, psoriasis, and psoriatic arthritis. Formycon and Fresenius Kabi announce EC marketing authorization for FYB202/Otulfi®, a biosimilar to Stelara®, valid in all EEA countries.
© Copyright 2024. All Rights Reserved by MedPath